HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Condition: Non-Small Cell Lung Cancer
Sponsor: Lantern Pharma Inc.
Full Title
LTRN300-2LC01-OR21: Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors (HARMONIC)
Eligibility/Info
Study for never smoker patients with an advanced or metastatic lung adenocarcinoma that have previously been treated with targeted therapy for an actionable genomic alteration.
Participants will be randomized 2:1 to receive one of the following treatment regimens:
Arm A: LP-300 + carboplatin + pemetrexed
Arm B: carboplatin + pemetrexed
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
